Wall Street analysts are actively shaping investor sentiment, and today’s research call activity reflects a dynamic landscape across various sectors. Several prominent firms issued upgrades and downgrades, alongside new coverage initiations, impacting a diverse range of companies. Key upgrades focused on boosting confidence in specific opportunities. TD Cowen elevated Ametek (AME) to a Buy rating with a price target of $230, driven by sustained high backlogs anticipated to fuel continued revenue and order growth. Piper Sandler also took a bullish stance, upgrading SEI Investments (SEIC) to an Overweight rating and a price target of $102, reflecting the firm’s belief that SEI will benefit significantly from the expanding alternatives investment market. CFRA similarly upgraded Pool Corp. (POOL) to a Buy rating, setting a price target of $304, signaling positive expectations for the company’s performance.
Conversely, several firms delivered downgrades, often citing concerns around visibility or expected headwinds. Evercore ISI lowered Coty (COTY) to an In Line rating with a $7 price target, attributing the move to diminished visibility regarding the timing and catalysts for potential value unlocks, alongside the current valuation of the company. Grupo Santander echoed this sentiment, downgrading Coty to Neutral with a $3.50 price target. BMO Capital Markets also downgraded Brown & Brown (BRO) to a Market Perform rating, reducing its price target to $88, primarily due to anticipated downward pressure on consensus organic growth estimates for 2026, which the firm believes could negatively impact investor sentiment. Piper Sandler initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and a $283 price target, capitalizing on the company’s potential for accelerated approval driven by FDA confirmation of clinical biomarker data and recent Breakthrough Therapy designation for Sanfilippo type B syndrome.
Furthermore, several new coverage initiations demonstrated confidence in emerging companies. LifeSci Capital initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and a $60 price target, highlighting the company’s “multiple quality shots on goal” including SION-719 as an add-on NBD1 stabilizer and proprietary dual-combination therapies. Oppenheimer initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and a $35 price target, recognizing the company’s development of a differentiated rare and common obesity franchise with a key readout expected next year. JonesResearch initiated coverage of Septerna (SEPN) with a Buy rating and a $43 price target, forecasting substantial peak sales potential for its lead endocrine program, SEP-479, targeting hypoparathyroidism, with an anticipated Phase 1 initiation in early 2026. Additionally, Loop Capital initiated coverage of Malibu Boats (MBUU) with a Buy rating and a $34 price target, factoring in the ongoing inventory rationalization period within the marine industry. Finally, several firms initiated coverage of Atai Beckley (ATAI) and Mind Medicine (MNMD), signaling confidence in their respective therapeutic approaches.
